Newest studies

Modes of covariation between vascular risk factors and cognition in cohorts with cultural and geographical variations

51/100 ✓ Peer-reviewed Risk factors Cerebral Circulation - Cognition and Behavior

Key finding: Then the mediation outputs will be used in the meta- analysis to assess the indirect effect estimates and variance of each significant brain mediator. +2 more findings

• Risk Factors
• Brain Scans

Full summary, score breakdown and related studies → Original source

Geospatial analysis of dementia mortality and its associations with demographic and socioeconomic factors

40/100 ✓ Peer-reviewed Risk factors Journal of Alzheimer s Disease Reports

Key finding: This study highlights diverse links between dementia mortality and demographic and socioeconomic factors at the county level in the United States. +4 more findings

• Health Equity

Full summary, score breakdown and related studies → Original source

Applying the Relational Job Design Theory to the Retail Industry: The Association between Perceived Social Impact and Job Satisfaction, Turnover Intention, and Persistence

37/100 ✓ Peer-reviewed Risk factors Health & Social Care in the Community

Key finding: The relational job design theory suggests that one’s perceived social impact (PSI) of their job contributes to improvements in job satisfaction, turnover intention, and persistence. +1 more finding

Full summary, score breakdown and related studies → Original source

Signalling Pathways Involved in Microglial Activation in Alzheimer's Disease and Potential Neuroprotective Role of Phytoconstituents

38/100 ✓ Peer-reviewed Drug development CNS & neurological disorders drug targets

Key finding: The pathophysiology of AD comprises Aβ, hyperphosphorylated tau protein formation, abrupt cholinergic cascade, oxidative stress, neuronal apoptosis, and neuroinflammation. +3 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease

35/100 ✓ Peer-reviewed Drug development Journal of Alzheimer's disease : JAD

Key finding: Alzheimer's disease (AD) is a neurodegenerative disease that imposes economic and societal burden. +3 more findings

• Treatments
• Clinical Trials
• Biomarkers

Full summary, score breakdown and related studies → Original source

omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases

48/100 ✓ Peer-reviewed Drug development American journal of human genetics

Key finding: The global population is aging, driving an urgent need for therapeutics that stop disease progression and eliminate symptoms. +3 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Medical, surgical, and physical treatments for Parkinson's disease

61/100 ✓ Peer-reviewed Digital health tools Lancet (London, England)

Key finding: Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from a multidisciplinary team, and important new approaches in the delivery of dopamine replacement are becoming available. +3 more findings

• Treatments
• Other Dementias

Full summary, score breakdown and related studies → Original source

The epidemiology of Parkinson's disease

61/100 ✓ Peer-reviewed Prevention and risk Lancet (London, England)

Key finding: The cause of Parkinson's disease is multifactorial, and involves genetic and environmental factors. +4 more findings

• Prevention
• Other Dementias
• Risk Factors

Full summary, score breakdown and related studies → Original source

Effects of Exercise on Urinary AD7c-NTP (Alzheimer-Associated Neuronal Thread Protein) Levels and Cognitive Function Among Active Korean Elderly: A Randomized Controlled Trial

51/100 ✓ Peer-reviewed Treatments Journal of Alzheimer's disease : JAD

Key finding: This is the first study to investigate urine biomarker through exercise intervention. +2 more findings

• Clinical Trials
• Diagnosis
• Lifestyle

Full summary, score breakdown and related studies → Original source

Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study

65/100 ✓ Peer-reviewed Treatments The journal of prevention of Alzheimer's disease

Key finding: There were no statistical differences between the placebo or solanezumab groups in CDR-G, CDR-SB, specific CDR boxes or CDR composite scores over the course of the trial. +2 more findings

Full summary, score breakdown and related studies → Original source

Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease

70/100 ✓ Peer-reviewed Treatments JAMA neurology

Key finding: At 6 months, compared with usual care, participants receiving the intervention had better QOL (QOL-AD score, 0.09 [95% CI, -0.63 to 0.82] vs -0.88 [95% CI, -1.62 to -0.13]; treatment effect estimate, 0.97; 95% CI, 0.07-1.86; P = .03). +3 more findings

• Caregiving

Full summary, score breakdown and related studies → Original source

Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial

81/100 ✓ Peer-reviewed Treatments JAMA internal medicine

Key finding: The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. +3 more findings

• Clinical Trials
• Risk Factors

Full summary, score breakdown and related studies → Original source

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study

64/100 ✓ Peer-reviewed Biomarkers The journal of prevention of Alzheimer's disease

Key finding: Both participant and study partner CFI increased over the duration of the study indicating worsening cognitive functioning. +2 more findings

Full summary, score breakdown and related studies → Original source

Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies

74/100 ✓ Peer-reviewed Biomarkers The journal of prevention of Alzheimer's disease

Key finding: In a large cohort of cognitively unimpaired individuals enrolled in a Phase 3 clinical trial and companion observational study, these findings confirm that higher baseline levels of amyloid and tau markers are associated with increased rates of cognitive decline and progression to functional impairment. +4 more findings

• Biomarkers
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration

44/100 ✓ Peer-reviewed Costs and economics Journal of Prevention of Alzheimer's Disease

Key finding: Burden of chronic intravenous treatments exceed the gross medical and social care cost savings and value of caregiver benefit. +2 more findings

• Treatments
• Policy
• Caregiving

Full summary, score breakdown and related studies → Original source

Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies

77/100 ✓ Peer-reviewed Biomarkers JAMA Neurology

Key finding: Of a total 912 participants, there were 499 males (54.7%) and 413 females (45.3%), and the mean (SD) age was 71.1 (8.49) years. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis

72/100 ✓ Peer-reviewed How common it is Lancet Healthy Longevity

Key finding: 4024 articles were identified, and 74 were included in our narrative synthesis. +1 more finding

• Risk Factors
• Prevention

Full summary, score breakdown and related studies → Original source

Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis

74/100 ✓ Peer-reviewed Treatments Annals of Family Medicine

Key finding: Although monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales in patients with Alzheimer dementia, these improvements are far below the MCID for each outcome and are accompanied by clinically meaningful harms. +1 more finding

• Treatments
• Side Effects
• Clinical Trials

Full summary, score breakdown and related studies → Original source

The diagnostic accuracy of the Mini-Cog screening tool for the detection of cognitive impairment—A systematic review and meta-analysis

73/100 ✓ Peer-reviewed Getting a diagnosis PLOS ONE

Key finding: 14 studies, 16 datasets, 7,194 total participants pooled +4 more findings

• Diagnosis

Full summary, score breakdown and related studies → Original source

Societal Costs of Dementia: 204 Countries, 2000-2019

47/100 ✓ Peer-reviewed Costs and economics Journal of Alzheimer's Disease

Key finding: Global direct healthcare spending on dementia was $260.6 billion in 2019 +3 more findings

• Policy

Full summary, score breakdown and related studies → Original source

Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US

68/100 ✓ Peer-reviewed Prevention and risk Alzheimer's & Dementia

Key finding: 1.09 million patients with type 2 diabetes, no prior Alzheimer's diagnosis, compared across 8 antidiabetic drug classes over 3-year follow-up +2 more findings

• Treatments
• Clinical Trials
• Diagnosis

Full summary, score breakdown and related studies → Original source

Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options

43/100 ✓ Peer-reviewed Risk factors Journal of the American Heart Association

Key finding: Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure.

• Risk Factors
• Treatments

Full summary, score breakdown and related studies → Original source

Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development

54/100 ✓ Peer-reviewed TREM2 and immune genetics Immunity

Key finding: Trem2 is essential for microglia-mediated synaptic refinement, but whether Trem2 contributes to shaping neuronal development remains unclear. +3 more findings

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities

46/100 ✓ Peer-reviewed Treatments Neurology

Key finding: The pathophysiology of ARIA has yet to be fully determined but may result from antibody-mediated breakdown of amyloid plaques releasing Aβ which is deposited in vessels leading to increased cerebral amyloid angiopathy or alterations in perivascular clearance or inflammation, possibly through complement activation.8.

• Treatments
• Side Effects
• Brain Scans

Full summary, score breakdown and related studies → Original source

Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies

59/100 ✓ Peer-reviewed Drug development Neurology

Key finding: Amyloid-related imaging abnormalities (ARIA) were the most common adverse events reported in the phase 3 ENGAGE and EMERGE trials of aducanumab, an anti-amyloid monoclonal antibody. +3 more findings

• Treatments
• Genetics
• Clinical Trials

Full summary, score breakdown and related studies → Original source